IEEE-Madison Section Meeting Final Reminder

IEEE-Madison Engineers in Medicine and Biology Chapter:
"Immuno-Autonomics: A Sea Change in Clinical Care"

• Wednesday, May 18th, 6:00 PM to 8:00 PM
• Talk by Dr, Andrew Holman, CEO of Inmedix, Inc.
• Joint Dinner Meeting with the Technical Club of Madison
• Location: 
        Imperial Garden 2039 Allen Blvd, Middleton, WI 53562
• Please Register at the Vtools Event page  here.
  
  Note: The May meeting will be a joint in person meeting with the Technical
  Club of Madison.  People usually start arriving at 6:00 pm and the talk
  begins at 7:00 pm.  Between these two times we can enjoy a nice family
  style Chinese dinner with all you can eat.  The cost for the dinner is
  $20, cash, at the meeting.  Anyone who wants to come must register by May 14 so that
  the restaurant prepares enough food. IEEE members who do not want food may attend at NO COST.

Abstract:  Twenty years after the launch of biologic treatments for patients with rheumatoid arthritis (RA), it has become increasingly apparent that only 25% of these patients treated achieve adequate success regardless of the immune target addressed.  The solution forced immunologists to seek answers in unexpected places and to rely on technology completely foreign to them.  The immune system is regulated by the brain, specifically the autonomic nervous system (ANS) which modulates fight-or-flight adrenaline and recovery phases.  It is measured best by heart rate variability (HRV) - a techniques used to quantify stress in over 50,000 peer-review studies.  In addition, the software, hardware, and firmware engineering of HRV has been significantly upgraded to enhance its precision.

This 5-min, next-generation HRV supports patients with autoimmune disease by applying a cardiovascular platform (ECG) to assess a brain function (ANS) to solve a clinical immunology problem.  It is first to predict 52-wk biologic outcome in RA with 90% sensitivity and 95.7% specificity in a prospective, double-blind trial.  Of equal importance, optimizing adverse (fight-or-flight predominant) ANS profile increased RA remission from 25% to 79%.  The new concept, called immuno-autonomics, represents a sea change in clinical care.

Bio: Dr. Holman is the founding rheumatologist at Pacific Rheumatology Associates Inc PS, Director of Research at Pacific Rheumatology Research Inc., a former President of the Northwest Rheumatism Society (2005) and a Clinical Associate Professor of Medicine at the University of Washington.   He has 25 year clinical and 19 year rheumatology research career experience with 16 lead author published papers, 25 lead author published abstracts.   For Inmedix, he has designed, completed and published 15 clinical studies, including FDA negotiations, involving nearly 1500 patients.

Research highlights include discovering and licensing use of dopamine agonists as a treatment of  fibromyalgia, applying autonomic nervous system (ANS) analysis with heart rate variability (HRV) to elevate treatment remission rates in patients with rheumatoid arthritis and other autoimmune diseases, and broadening understanding of pain in patients with PC3 (positional cervical cord compression) using dynamic cervical magnetic resonance imaging (dMRI).